Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study
Launched by PEKING UNIVERSITY · Feb 12, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a digital therapy program designed to help people with depression. The therapy is based on a method called cognitive behavioral therapy (CBT), which helps individuals change negative thought patterns and behaviors. Participants will use a specially developed mobile app over 8 weeks, engaging in weekly sessions with guidance from artificial intelligence, along with completing homework assignments. Researchers want to find out how well this digital therapy works in real-life situations and learn more about its effects on the brain and genetics.
To be eligible for this trial, participants should be between 14 and 60 years old, have a depression score indicating moderate to severe symptoms, and be willing to provide consent to participate. However, individuals with severe suicidal thoughts cannot join the study. If you participate, you can expect to use the app regularly and receive support throughout the 8-week program. This study is still in the planning stages and is not yet recruiting participants, but it aims to offer a new way to support people struggling with depression.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 14-60 years (including 14 and 60), no gender restriction;
- • 2. HAMD \>= 17;
- • 3. Written informed consent obtained from the patient; written informed consent obtained from the guardian for minors.
- Exclusion Criteria:
- • Persons with severe suicidal tendencies (item 10 of the MADRS scale ≥ 5).
About Peking University
Peking University is a prestigious institution located in Beijing, China, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, Peking University leverages its extensive academic resources and collaborative networks to drive innovative healthcare solutions. The university's focus on rigorous scientific methodologies and adherence to ethical standards ensures the integrity and reliability of its clinical research initiatives. By fostering interdisciplinary partnerships, Peking University aims to translate groundbreaking discoveries into tangible health benefits, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported